Skip to main content
. Author manuscript; available in PMC: 2016 Jan 15.
Published in final edited form as: Clin Cancer Res. 2015 Apr 15;21(14):3347–3355. doi: 10.1158/1078-0432.CCR-15-0057

Figure 3. Clinical outcome and T cell response according to tumor molecular subtype in TCGA endometrial cancers.

Figure 3

(A) Kaplan-Meier curves demonstrating recurrence-free survival of POLE wild-type, microsatellite stable (MSS, n=147), microsatellite unstable (MSI, n=63) and POLE proofreading mutant (POLE, n=18) ECs in the TCGA series (note that survival data were not available for all cases). Comparison between subgroups was made by two-sided log-rank test. (B) Leucocyte methylation scores according to EC molecular subtype. Unadjusted comparison between groups was made by two-sided Mann-Whitney test. ** indicates P<0.01. (C) Gene set enrichment analysis (GSEA) of 200-gene tumor-associated T cell signature (Ref. 18) in POLE-mutant ECs compared to other tumors. Raw RNAseq counts were normalized and ranked using DESeq prior to GSEA analysis with pre-ranking. (D) Heatmap showing expression of immunological genes according to EC molecular subtype. RSEM-normalised RNAseq expression data were log2 transformed, zero centred and assigned unit variance. For each gene, the mean fold change in expression in POLE mutants relative to MSS ECs was calculated and expression compared between POLE mutants, MSS and MSI ECs by unadjusted, two-sided Mann-Whitney test.